Prescription medicine
Apraclonidine Brand names: Iopidine
Apraclonidine (Iopidine) is a prescription medicine with an FDA approval on record since 1987. No generic is listed; pharmacies paid $9.29 per mL (Apraclonidine HCl 0.5% drops) in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the apraclonidine FDA label on DailyMed (effective May 8, 2026, Harrow Eye, LLC); the NDA 19779 record on Drugs@FDA; every apraclonidine label on DailyMed.
Highlights of the record
FDA label of May 8, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageIOPIDINE 1% Ophthalmic Solution is indicated to control or prevent post-surgical elevations in IOP that occur in patients after argon laser trabeculoplasty, argon laser iridotomy or Nd:YAG posterior capsulotomy.
Forms and strengths
- 5.75 mg/ml
- 10 mg/ml
Solution/ drops; solution.
On the market
- Earliest approval on file
- December 31, 1987 Iopidine, Harrow Eye; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 1 first March 12, 2009; 1 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 2 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $9.29 per mL Apraclonidine HCl 0.5% drops
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 1 since 2022 0 Class I among all firms' recalls; latest April 13, 2022
- FAERS reports
- 106 through July 30, 2026
What is apraclonidine used for?
From the label: indications and usageIOPIDINE 1% Ophthalmic Solution is indicated to control or prevent post-surgical elevations in IOP that occur in patients after argon laser trabeculoplasty, argon laser iridotomy or Nd:YAG posterior capsulotomy.
FDA pharmacologic class: alpha-Adrenergic Agonist.
Source: FDA drug label (IOPIDINE 1%), Harrow Eye, LLC, effective May 8, 2026 (SPL set 00f18845-ccde-8678-e063-6294a90a3374), via openFDA; the full label on DailyMed
Is there a generic for apraclonidine (Iopidine)?
The FDA approved the first generic apraclonidine on March 12, 2009. 1 generic application is approved; 1 of it carries a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
- 1987 earliest approval on file
- 2009 first generic approved
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for apraclonidine (Iopidine)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $9.29 per mL (Apraclonidine HCl 0.5% drops), up 7% from $8.71 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Apraclonidine HCl 0.5% drops (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Apraclonidine HCl 0.5% drops | Generic | $9.29 per mL | n/a | +7% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has apraclonidine been recalled?
The FDA's Enforcement Report lists 1 recall naming apraclonidine since 2022: 0 Class I (the most serious), 1 Class II, 0 Class III; 0 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| April 13, 2022 | Class II | Mckesson Medical-Surgical Inc. Corporate Office | cGMP deviations: Temperature abuse |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the apraclonidine label say about other medicines?
The apraclonidine label names 1 other medicine in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Clonidine | contraindications | CONTRAINDICATIONS IOPIDINE 1% Ophthalmic Solution is contraindicated for patients receiving monoamine oxidase inhibitor therapy and for patients with hypersensitivity to any component of this medication or to clonidine. |
Source: FDA drug label (IOPIDINE 1%), Harrow Eye, LLC, effective May 8, 2026 (SPL set 00f18845-ccde-8678-e063-6294a90a3374), via openFDA; the full label on DailyMed
What do FAERS reports show for apraclonidine?
The FDA Adverse Event Reporting System holds 106 reports that list apraclonidine among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 2 are coded as a death and 30 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other alpha-adrenergic agonists
- the pharmacologic class, with prices and generics
- Apraclonidine side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other